Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what steps he is taking to increase access to weight loss injections for long-term conditions.

Weight loss injections are currently recommended for use on the National Health Service for the treatment of obesity and/or type 2 diabetes. To be routinely used in the NHS in England, a medicine normally needs a marketing authorisation from the Medicines and Healthcare Products Regulatory Agency (MHRA) that shows it is safe and efficacious, and then a positive National Institute for Health and Care Excellence (NICE) appraisal to show if it is a clinically and cost-effective use of NHS resources. NICE is currently developing guidance on the use of semaglutide for the prevention of cardiovascular disease and, subject to licensing, liver fibrosis, without cirrhosis, caused by metabolic dysfunction-associated steatohepatitis.

Most recently, NICE recommended semaglutide, brand name Wegovy, and tirzepatide, brand name Mounjaro, as treatments for obesity, in adults with a high body mass index and at least one weight-related comorbidity such as type 2 diabetes, hypertension, and/or cardiovascular disease.

Until recently, these medicines were only available in specialist weight management services. From 23 June tirzepatide started to become available in primary care. This will help to increase access. Access is being prioritised for those with the highest clinical need first. The NHS will look at different service models including digital and community options and the roll out will be sped up if possible. As set out in the Government’s new 10-Year Health Plan, we are committed to expanding access to these medicines and will work closely with industry and local systems to test new models of care and identify innovative ways to do this.